ScoreWhy is Shanxi C&Y Pharmaceutical Group Co., Ltd. ?
1
Poor Management Efficiency with a low ROCE of 2.56%
- The company has been able to generate a Return on Capital Employed (avg) of 2.56% signifying low profitability per unit of total capital (equity and debt)
2
High Debt Company with a Debt to Equity ratio (avg) at times
- Poor long term growth as Net Sales has grown by an annual rate of -0.28% and Operating profit at 20.46% over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at times
- The company has been able to generate a Return on Equity (avg) of 7.73% signifying low profitability per unit of shareholders funds
3
Poor long term growth as Net Sales has grown by an annual rate of -0.28% and Operating profit at 20.46% over the last 5 years
4
Flat results in Sep 25
- NET PROFIT(HY) At CNY 11.94 MM has Grown at -53.86%
- INTEREST(HY) At CNY 11.68 MM has Grown at 41.99%
- CASH AND EQV(HY) Lowest at CNY 221.38 MM
5
With ROE of 16.56%, it has a very expensive valuation with a 10.17 Price to Book Value
- Over the past year, while the stock has generated a return of 13.90%, its profits have fallen by -64.9%
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Shanxi C&Y Pharmaceutical Group Co., Ltd. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Shanxi C&Y Pharmaceutical Group Co., Ltd.
19.5%
0.59
47.06%
China Shanghai Composite
13.33%
0.90
14.74%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-0.28%
EBIT Growth (5y)
20.46%
EBIT to Interest (avg)
-0.09
Debt to EBITDA (avg)
9.89
Net Debt to Equity (avg)
1.37
Sales to Capital Employed (avg)
0.92
Tax Ratio
10.33%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
2.56%
ROE (avg)
7.73%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
61
Industry P/E
Price to Book Value
10.17
EV to EBIT
52.97
EV to EBITDA
25.35
EV to Capital Employed
4.65
EV to Sales
3.67
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
8.78%
ROE (Latest)
16.56%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend13What is working for the Company
RAW MATERIAL COST(Y)
Fallen by -4.12% (YoY
NET SALES(Q)
Highest at CNY 238.48 MM
OPERATING PROFIT(Q)
Highest at CNY 43.09 MM
OPERATING PROFIT MARGIN(Q)
Highest at 18.07 %
PRE-TAX PROFIT(Q)
Highest at CNY 40.51 MM
NET PROFIT(Q)
Highest at CNY 21.95 MM
EPS(Q)
Highest at CNY 0.09
-18What is not working for the Company
NET PROFIT(HY)
At CNY 11.94 MM has Grown at -53.86%
INTEREST(HY)
At CNY 11.68 MM has Grown at 41.99%
CASH AND EQV(HY)
Lowest at CNY 221.38 MM
DEBTORS TURNOVER RATIO(HY)
Lowest at 4.52 times
Here's what is working for Shanxi C&Y Pharmaceutical Group Co., Ltd.
Net Profit
At CNY 21.95 MM has Grown at 868.03%
over average net sales of the previous four periods of CNY 2.27 MMMOJO Watch
Near term Net Profit trend is very positive
Net Profit (CNY MM)
Pre-Tax Profit
At CNY 40.51 MM has Grown at 151.07%
over average net sales of the previous four periods of CNY 16.13 MMMOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (CNY MM)
Net Sales
Highest at CNY 238.48 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (CNY MM)
Net Sales
At CNY 238.48 MM has Grown at 16.55%
over average net sales of the previous four periods of CNY 204.62 MMMOJO Watch
Near term sales trend is positive
Net Sales (CNY MM)
Operating Profit
Highest at CNY 43.09 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (CNY MM)
Operating Profit Margin
Highest at 18.07 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Pre-Tax Profit
Highest at CNY 40.51 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (CNY MM)
Net Profit
Highest at CNY 21.95 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (CNY MM)
EPS
Highest at CNY 0.09
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (CNY)
Raw Material Cost
Fallen by -4.12% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Shanxi C&Y Pharmaceutical Group Co., Ltd.
Interest
At CNY 11.68 MM has Grown at 41.99%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (CNY MM)
Cash and Eqv
Lowest at CNY 221.38 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
Debtors Turnover Ratio
Lowest at 4.52 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling Debtors has slowed
Debtors Turnover Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
